Overview

* Caribou Biosciences ( CRBU ) Q3 net loss of $27.5 mln, with licensing revenue at $2.2 mln

* R&D expenses decreased due to reduced clinical trial activities and workforce reduction

* Company maintains $159.2 mln in cash for funding operations into 2H 2027

Outlook

* Caribou expects to fund operations into 2H 2027 with current resources

Result Drivers

* Research and development expenses were $22.4 million for the three months ended September 30, 2025, compared to $30.4 million for the same period in 2024.

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $2.20

Licensin mln

g and

Collabor

ation

Revenue

Q3 Net -$27.55

Income mln

Q3 Basic -$0.30

EPS

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Caribou Biosciences Inc ( CRBU ) is $8.50, about 73.6% above its November 11 closing price of $2.24

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)